CDK2 and breast cancer: Eighteen of the 30 targets, including ErbB4 (ERBB4), EGFR, CDK2, CDK6, p38 MAPK (MAPK14), ERK2 (MAPK1), Lck (LCK), Src (SRC), IGF1R, PI3Kγ (PIK3CG), VEGFR2 (KDR), aromatase (CYP19A1), PTP1B (PTPN1), SHP2 (PTPN11), caspase-3 (CASP3), PARP-1, HSP90α (HSP90AA1) and HSC70 (HSPA8), were identified as the anti-breast cancer targets of LF triterpenoids.